CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Valo Health today announced that industry leader Brian M. Alexander, M.D., M.P.H. has been ...

Valo to leverage human causal biology expertise to uncover new insights about NOD2 as a potential Parkinson’s disease drug target LEXINGTON, Mass., September 09, 2025--(BUSINESS WIRE)--Valo Health, ...

Collaboration will apply Valo’s Opal Computational Platform™ and real-world patient dataset to enable the discovery and development of novel cardiometabolic drug programmes Novo Nordisk licenses three ...

Valo Health, Inc. (“Valo”), a biotechnology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence (AI), today announced the ...

The collaboration could expand to 'the entire drug discovery continuum', the two companies say. Novo Nordisk and Boston-based Valo Health, Inc. this week announced the launch of a collaboration that ...

Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to 20 novel drug programmes in obesity, type 2 diabetes, and cardiovascular ...

Valo Health’s merger with a Khosla Ventures special purpose acquisition company has gone belly up. The partners terminated the deal, which would have left Valo with $750 million before expenses, ...

Valo Health, Inc. ("Valo"), a company pioneering the use of human data and AI to accelerate drug discovery and development, today announced the appointment of Rita Kale as Chief Financial Officer (CFO ...

BOSTON, March 15, 2022 /PRNewswire/ -- Valo Health, LLC ("Valo"), the technology company built focused on transforming the drug discovery and development process using human-centric data and ...

It’s no secret that developing a new therapeutic is a slow and expensive process. On average it takes over a decade to take a drug from idea to market, and a recent estimate in the Journal of the ...